Stefan N. Lukianov, AM MS

The FDA has approved Libtayo for the treatment of patients with locally advanced and metastatic basal cell carcinoma (laBCC) who have previously received a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate